Changes of general cerebral symptoms in patients with traumatic brain injury and their dependence on the -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene

Potapov, Oleksandr Oleksandrovych; Kmyta, Oleksii Petrovych

doi:10.14739/2310-1237.2016.1.71577

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous evidence has demonstrated that alternative treatment procedures combining drainage and intraventricular fibrinolysis with recombinant tissue plasminogen activator may prevent haemorrhagic complications (25). Notably, a previous study has reported the changes of focal and brainstem neurological signs in patients with traumatic brain injury and their dependence on the -675 4/5 G polymorphism in the PAI-1 gene (26). Therefore, in the present study it was assumed that plasma PAI-1 level may be associated with the degree of Parkinson's disease.…”

Section: Discussionmentioning

confidence: 99%

Role of plasminogen activator inhibitor‑1 in the diagnosis and prognosis of patients with Parkinson's disease

Pan

Zhao

Zhai³

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

Parkinson's disease is a neurodegenerative disease that frequently results in memory disorders, cognitive decline and dementia. Previous studies have reported that plasminogen activator inhibitor-1 (PAI-1) serves an important role in cardiovascular disease risk, adiposity, insulin resistance and inflammation. However, the role of PAI-1 in diagnosis and prognosis of patients with Parkinson's disease following deep brain stimulation (DBS) has not reported, to the best of our knowledge. Therefore, the purpose of the present study was to investigate the clinical significance of PAI-1 in patients with Parkinson's disease. Plasma PAI-1 levels were measured in 102 patients with Parkinson's disease who underwent DBS. It was demonstrated that plasma PAI-1 levels were significantly increased in patients with Parkinson's disease compared with healthy individuals (P<0.01). Patients with Parkinson's disease received DBS presented significantly improved cognitive competence compared with controls (P<0.01). DBS significantly decreased plasma PAI-1 levels in patients with Parkinson's disease compared with controls (P<0.05). It was also observed that plasma PAI-1 levels were significantly negatively associated with cognitive function for patients with Parkinson's disease (P<0.01). In conclusion, these findings demonstrated that the degree of Parkinson's disease severity is positively associated with circulating levels of plasma PAI-1 levels, which suggests that PAI-1 may be a potential diagnostic and prognostic marker for patients with Parkinson's disease.

show abstract

Section: Discussionmentioning

confidence: 99%